Intepirdine as adjunctive therapy to donepezil for mild‐to‐moderate Alzheimer's disease: A randomized, placebo‐controlled, phase 3 clinical trial (MINDSET)

Intepirdine as adjunctive therapy to donepezil for mild‐to‐moderate Alzheimer's disease: A randomized, placebo‐controlled, phase 3 clinical trial (MINDSET)

Abstract Introduction A previous phase 2b study supported the use of the 5‐HT6 receptor antagonist intepirdine as adjunctive therapy to donepezil for Alzheimer's disease (AD) dementia. A phase 3 study, MINDSET, was performed to test this hypothesis. Methods MINDSET was a global, double‐blind, r...

Full description

Bibliographic Details
Main Authors: Frederick M. Lang, Yi Mo, Marwan Sabbagh, Paul Solomon, Merce Boada, Roy W. Jones, Giovanni B. Frisoni, Timo Grimmer, Bruno Dubois, Mark Harnett, Sarah R. Friedhoff, Shari Coslett, Jeffrey L. Cummings
Format: Article
Language:English
Published: Wiley 2021-01-01
Series:Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Subjects:
5‐HT6
Alzheimer's disease
clinical trial
intepirdine
phase 3
Online Access:https://doi.org/10.1002/trc2.12136

Internet

https://doi.org/10.1002/trc2.12136

Similar Items